$BLUE
bluebird bio, Inc.

2015 Q2 Form 10-Q Financial Statement

#000156459015003433 Filed on May 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $4.940M $6.344M $6.386M
YoY Change -22.02% 0.14% 0.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.70M $7.300M $5.300M
YoY Change 87.72% 32.73% 12.77%
% of Gross Profit
Research & Development $44.27M $23.72M $20.50M
YoY Change 217.75% 106.92% 109.18%
% of Gross Profit
Depreciation & Amortization $1.800M $1.710M $1.670M
YoY Change 233.33% 256.25% 406.06%
% of Gross Profit
Operating Expenses $56.96M $31.27M $25.80M
YoY Change 189.61% 83.91% 77.93%
Operating Profit -$52.02M -$24.93M -$19.61M
YoY Change 290.15% 133.65% 141.7%
Interest Expense -$2.000M -$200.0K -$200.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $228.0K $139.0K $100.0K
YoY Change 1972.73% 135.59%
Pretax Income -$51.80M -$24.79M -$19.50M
YoY Change 288.76% 133.84% 140.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$51.80M -$24.79M -$19.54M
YoY Change 3294.17% 133.64% 141.85%
Net Earnings / Revenue -1048.48% -390.72% -306.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.570M -$760.7K -$663.3K
COMMON SHARES
Basic Shares Outstanding 32.83M 32.57M 28.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $810.5M $334.9M $473.6M
YoY Change 361.3% 73.97% 129.59%
Cash & Equivalents $593.3M $133.2M $347.8M
Short-Term Investments $217.2M $201.7M $125.7M
Other Short-Term Assets $4.900M $5.900M $6.400M
YoY Change -31.94% 73.53% 12.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $815.5M $340.8M $480.0M
YoY Change 345.95% 73.97% 126.42%
LONG-TERM ASSETS
Property, Plant & Equipment $16.80M $16.85M $15.74M
YoY Change 30.67% 40.6% 44.14%
Goodwill $13.13M $13.13M
YoY Change
Intangibles $27.28M $28.22M
YoY Change
Long-Term Investments $125.9M $134.4M $18.40M
YoY Change
Other Assets $1.500M $1.294M $1.215M
YoY Change -11.76% -19.13% -18.07%
Total Long-Term Assets $183.7M $193.0M $76.75M
YoY Change 218.08% 1320.01% 518.8%
TOTAL ASSETS
Total Short-Term Assets $815.5M $340.8M $480.0M
Total Long-Term Assets $183.7M $193.0M $76.75M
Total Assets $999.2M $533.8M $556.7M
YoY Change 315.26% 154.79% 148.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.300M $2.551M $2.954M
YoY Change -11.06% -1.92% -32.23%
Accrued Expenses $15.30M $15.10M $12.70M
YoY Change 30.77% 190.38% 159.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.00M $42.01M $42.98M
YoY Change -29.2% 27.13% 23.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $51.80M $265.0K $294.0K
YoY Change 14615.91% -31.17% 41.35%
Total Long-Term Liabilities $51.80M $265.0K $294.0K
YoY Change 14615.91% -31.17% 41.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.00M $42.01M $42.98M
Total Long-Term Liabilities $51.80M $265.0K $294.0K
Total Liabilities $80.20M $59.32M $65.48M
YoY Change 7.12% -9.22% -9.96%
SHAREHOLDERS EQUITY
Retained Earnings -$172.2M -$147.4M
YoY Change 57.54% 49.36%
Common Stock $327.0K $323.0K
YoY Change 34.57% 35.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $919.0M $474.5M $491.3M
YoY Change
Total Liabilities & Shareholders Equity $999.2M $533.8M $556.7M
YoY Change 315.26% 154.79% 148.11%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$51.80M -$24.79M -$19.54M
YoY Change 3294.17% 133.64% 141.85%
Depreciation, Depletion And Amortization $1.800M $1.710M $1.670M
YoY Change 233.33% 256.25% 406.06%
Cash From Operating Activities -$12.12M -$24.16M -$15.66M
YoY Change 6.97% 102.51% 186.81%
INVESTING ACTIVITIES
Capital Expenditures -$1.410M $1.156M -$2.410M
YoY Change -29.85% -54.07% -54.44%
Acquisitions
YoY Change
Other Investing Activities -$6.580M -$191.8M $30.00M
YoY Change 40.9%
Cash From Investing Activities -$7.990M -$193.0M $27.60M
YoY Change 19.43% 7557.94% -621.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.464M
YoY Change 267.21%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 480.2M 2.460M 246.3M
YoY Change 38943.9% 267.16% 106991.3%
NET CHANGE
Cash From Operating Activities -12.12M -24.16M -15.66M
Cash From Investing Activities -7.990M -193.0M 27.60M
Cash From Financing Activities 480.2M 2.460M 246.3M
Net Change In Cash 460.1M -214.7M 258.3M
YoY Change -2840.5% 1457.91% -2554.85%
FREE CASH FLOW
Cash From Operating Activities -$12.12M -$24.16M -$15.66M
Capital Expenditures -$1.410M $1.156M -$2.410M
Free Cash Flow -$10.71M -$25.32M -$13.25M
YoY Change 14.91% 75.23% 7694.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6670000
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32693000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
6344000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-123000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
474499000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533816000
CY2015Q1 us-gaap Liabilities
Liabilities
59317000
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
327000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646466000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172171000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
294000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
638389000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-147384000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
491257000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
556739000
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5302000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6321000
CY2014Q4 us-gaap Liabilities
Liabilities
65482000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
323000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32829440
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24333000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1913000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32693000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23719000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7336000
CY2015Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
215000
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
31270000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
17003000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24926000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10668000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
139000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
59000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-24787000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-10609000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24839000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10609000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24148000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1710000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
475000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5432000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-71000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32340000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4039000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
340836000
CY2015Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
134430000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16850000
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27278000
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15129000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32340000
CY2015Q1 us-gaap Goodwill
Goodwill
13128000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1294000
CY2015Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1913000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8456000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15740000
CY2015Q1 us-gaap Assets
Assets
533816000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2551000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
42013000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28219000
CY2014Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
85000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5540000
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
265000
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
6250000
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32558000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2014Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
6796000
CY2015Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1913000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1913000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8674000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4521000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
479989000
CY2014Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
18448000
CY2014Q4 us-gaap Goodwill
Goodwill
13128000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1215000
CY2014Q4 us-gaap Assets
Assets
556739000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2954000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14649000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25375000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42978000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2493000
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
42000
CY2015Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
130000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2064000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-331000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2388000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
88000
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1738000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6344000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6335000
CY2015Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-270000
CY2014Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
586000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24159000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11934000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1156000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2517000
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223020000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31200000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-192976000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2517000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2464000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
671000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2464000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
671000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-214671000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13780000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
206279000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192499000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1125000
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
947000
CY2015Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of severe genetic and rare diseases and in the field of T cell-based immunotherapy. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations. </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:2.27%;font-size:10pt;">&nbsp;</p></div>
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes. Actual results could materially differ from those estimates.&nbsp;&nbsp;</p></div>
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
336263000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
144229000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2015Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
145000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
336140000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
144158000
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
469314000
CY2015Q1 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
7011000
CY2014Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
492003000
CY2015Q1 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2015Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
248000000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
134400000
CY2015Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2014Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2015Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
300000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
1300000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1000000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5432000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2493000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
3000000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3652000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
776000
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
347000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4074000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1297000
CY2015Q1 blue Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3997000
CY2015Q1 blue Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.07
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
25.16
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.80
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.91
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
29.12
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.30
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
96.74
CY2015Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2400000
CY2015Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
200000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4525000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4709000

Files In Submission

Name View Source Status
0001564590-15-003433-index-headers.html Edgar Link pending
0001564590-15-003433-index.html Edgar Link pending
0001564590-15-003433.txt Edgar Link pending
0001564590-15-003433-xbrl.zip Edgar Link pending
blue-10q_20150331.htm Edgar Link pending
blue-20150331.xml Edgar Link completed
blue-20150331.xsd Edgar Link pending
blue-20150331_cal.xml Edgar Link unprocessable
blue-20150331_def.xml Edgar Link unprocessable
blue-20150331_lab.xml Edgar Link unprocessable
blue-20150331_pre.xml Edgar Link unprocessable
blue-ex1010_20150331485.htm Edgar Link pending
blue-ex1017_20150331120.htm Edgar Link pending
blue-ex311_201503316.htm Edgar Link pending
blue-ex312_201503318.htm Edgar Link pending
blue-ex321_201503317.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending